Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Gastroenterology Reports
Published in: Current Gastroenterology Reports 7/2015

01-07-2015 | Inflammatory Bowel Disease (SB Hanauer, Section Editor)

Clinical Utility of Biomarkers in IBD

Authors: Gerhard Rogler, Luc Biedermann

Published in: Current Gastroenterology Reports | Issue 7/2015

Login to get access

Abstract

There is no gold standard for the diagnosis and monitoring of inflammatory bowel diseases (IBD). Biomarkers are useful tools for the management of patients suffering from IBD. However, they should be used only when their additional information is useful for clinical decision-making. In principal, four situations during the management of an individual IBD patient can be discriminated from a clinical standpoint in which biomarkers provide useful information. First, biomarkers may be helpful when the diagnosis of IBD is established and aid in the discrimination between ulcerative colitis (UC) and Crohn’s disease (CD) is necessary. Second, biomarkers may be helpful in the prognostic evaluation of IBD severity or disease behavior and for early decisions on the best treatment. The third situation in which biomarkers are useful is the evaluation of disease activity during the disease course, for monitoring and for guidance of ongoing treatment. Finally, the fourth typical situation when biomarkers are of value is after surgery to predict or diagnose a relapse of the disease. From a clinical point of view, it may be more useful to discuss specific biomarkers and their individual value and impact in these four prototypic situations than to sum up advantages and disadvantages for each biomarker isolated from the clinical situation. Therefore, this overview is structured in chapters reflecting those four typical situations during the disease course of IBD patents to critically evaluate the potential and value of each of the biomarkers in the specific situation.
Literature
1.
2.
Biomarkers Definitions Working G. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69(3):89–95.
3.
Burri E, Beglinger C. The use of fecal calprotectin as a biomarker in gastrointestinal disease. Exp Rev Gastroenterol Hepatol. 2014;8(2):197–210.
4.
Dubinsky MC. Clinical perspectives in Crohn’s disease. Serologic and prognostic biomarkers: who, when, and how? Rev Gastroenterol Disord. 2007;7 Suppl 2:S3–7.PubMed
5.
Li X, Conklin L, Alex P. New serological biomarkers of inflammatory bowel disease. World J Gastroenterol. 2008;14(33):5115–24.PubMedCentralPubMed
6.
Barahona-Garrido J, Sarti HM, Barahona-Garrido MK, Hernandez-Calleros J, Coss-Adame E, Garcia-Saenz SM, et al. Serological markers in inflammatory bowel disease: a review of their clinical utility. Rev Gastroenterol Mex. 2009;74(3):230–7.PubMed
7.
Ferrante M, Henckaerts L, Joossens M, Pierik M, Joossens S, Dotan N, et al. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut. 2007;56(10):1394–403.PubMedCentralPubMed
8.
Gupta SK, Fitzgerald JF, Croffie JM, Pfefferkorn MD, Molleston JP, Corkins MR. Comparison of serological markers of inflammatory bowel disease with clinical diagnosis in children. Inflamm Bowel Dis. 2004;10(3):240–4.PubMed
9.
Mokrowiecka A, Daniel P, Slomka M, Majak P, Malecka-Panas E. Clinical utility of serological markers in inflammatory bowel disease. Hepatogastroenterology. 2009;56(89):162–6.PubMed
10.
Papp M, Altorjay I, Dotan N, Palatka K, Foldi I, Tumpek J, et al. New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohort. Am J Gastroenterol. 2008;103(3):665–81.PubMed
11.
Papp M, Norman GL, Altorjay I, Lakatos PL. Utility of serological markers in inflammatory bowel diseases: gadget or magic? World J Gastroenterol. 2007;13(14):2028–36.PubMedCentralPubMed
12.
Plevy S. Do serological markers and cytokines determine the indeterminate? J Clin Gastroenterol. 2004;38(5 Suppl 1):S51–6.PubMed
13.••
Tung CC, Wong JM, Lee WC, Liu HH, Chang CH, Chang MC, et al. Combining TNFSF15 and ASCA IgA can be used as a predictor for the stenosis/perforating phenotype of Crohn’s disease. J Gastroenterol Hepatol. 2014;29(4):723–9. An attempt to find biomarkers for the prediction of disease courses in Crohn’s disease illustrating the associated problems.PubMed
14.
Eser A, Papay P, Primas C, Pernicka E, Harrer M, Dejaco C, et al. The impact of intestinal resection on serum levels of anti-Saccharomyces cerevisiae antibodies (ASCA) in patients with Crohn’s disease. Aliment Pharmacol Ther. 2012;35(2):292–9.PubMed
15.
Standaert-Vitse A, Sendid B, Joossens M, Francois N, Vandewalle-El Khoury P, Branche J, et al. Candida albicans colonization and ASCA in familial Crohn’s disease. Am J Gastroenterol. 2009;104(7):1745–53.PubMed
16.
Schoepfer AM, Flogerzi B, Seibold-Schmid B, Schaffer T, Kun JF, Pittet V, et al. Low Mannan-binding lectin serum levels are associated with complicated Crohn’s disease and reactivity to oligomannan (ASCA). Am J Gastroenterol. 2009;104(10):2508–16.PubMed
17.
Schaffer T, Muller S, Flogerzi B, Seibold-Schmid B, Schoepfer AM, Seibold F. Anti-Saccharomyces cerevisiae mannan antibodies (ASCA) of Crohn’s patients crossreact with mannan from other yeast strains, and murine ASCA IgM can be experimentally induced with Candida albicans. Inflamm Bowel Dis. 2007;13(11):1339–46.PubMed
18.
Mokrowiecka A, Gasiorowska A, Malecka-Panas E. pANCA and ASCA in the diagnosis of different subtypes of inflammatory bowel disease. Hepatogastroenterology. 2007;54(77):1443–8.PubMed
19.
Seibold F. ASCA: genetic marker, predictor of disease, or marker of a response to an environmental antigen? Gut. 2005;54(9):1212–3.PubMedCentralPubMed
20.
Dubinsky MC. What is the role of serological markers in the diagnosis of IBD? Inflamm Bowel Dis. 2008;14 Suppl 2:S185–6.PubMed
21.
Spivak J, Landers CJ, Vasiliauskas EA, Abreu MT, Dubinsky MC, Papadakis KA, et al. Antibodies to I2 predict clinical response to fecal diversion in Crohn’s disease. Inflamm Bowel Dis. 2006;12(12):1122–30.PubMed
22.
Joossens S, Colombel JF, Landers C, Poulain D, Geboes K, Bossuyt X, et al. Anti-outer membrane of porin C and anti-I2 antibodies in indeterminate colitis. Gut. 2006;55(11):1667–9.PubMedCentralPubMed
23.
Mei L, Targan SR, Landers CJ, Dutridge D, Ippoliti A, Vasiliauskas EA, et al. Familial expression of anti-Escherichia coli outer membrane porin C in relatives of patients with Crohn’s disease. Gastroenterology. 2006;130(4):1078–85.PubMed
24.
Wei B, Dalwadi H, Gordon LK, Landers C, Bruckner D, Targan SR, et al. Molecular cloning of a Bacteroides caccae TonB-linked outer membrane protein identified by an inflammatory bowel disease marker antibody. Infect Immun. 2001;69(10):6044–54.PubMedCentralPubMed
25.
Shen C, Landers CJ, Derkowski C, Elson CO, Targan SR. Enhanced CBir1-specific innate and adaptive immune responses in Crohn’s disease. Inflamm Bowel Dis. 2008;14(12):1641–51.PubMedCentralPubMed
26.
Fleshner P, Ippoliti A, Dubinsky M, Vasiliauskas E, Mei L, Papadakis KA, et al. Both preoperative perinuclear antineutrophil cytoplasmic antibody and anti-CBir1 expression in ulcerative colitis patients influence pouchitis development after ileal pouch-anal anastomosis. Clin Gastroenterol Hepatol. 2008;6(5):561–8.PubMedCentralPubMed
27.
Papadakis KA, Yang H, Ippoliti A, Mei L, Elson CO, Hershberg RM, et al. Anti-flagellin (CBir1) phenotypic and genetic Crohn’s disease associations. Inflamm Bowel Dis. 2007;13(5):524–30.PubMed
28.
Targan SR, Landers CJ, Yang H, Lodes MJ, Cong Y, Papadakis KA, et al. Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn’s disease. Gastroenterology. 2005;128(7):2020–8.PubMed
29.
Rieder F, Schleder S, Wolf A, Dirmeier A, Strauch U, Obermeier F, et al. Serum anti-glycan antibodies predict complicated Crohn’s disease behavior: a cohort study. Inflamm Bowel Dis. 2010;16(8):1367–75.PubMed
30.
Deusch K, Oberstadt K, Schaedel W, Weber M, Classen M. p-ANCA as a diagnostic marker in ulcerative colitis. Adv Exp Med Biol. 1993;336:527–31.PubMed
31.
Rump JA, Worner I, Roth M, Scholmerich J, Hansch M, Peter HH. p-ANCA of undefined specificity in ulcerative colitis: correlation to disease activity and therapy. Adv Exp Med Biol. 1993;336:507–13.PubMed
32.
Saibeni S, Folli C, de Franchis R, Borsi G, Vecchi M. Diagnostic role and clinical correlates of anti-Saccharomyces cerevisiae antibodies (ASCA) and anti-neutrophil cytoplasmic antibodies (p-ANCA) in Italian patients with inflammatory bowel diseases. Dig Liver Dis. 2003;35(12):862–8.PubMed
33.
Schoepfer AM, Schaffer T, Mueller S, Flogerzi B, Vassella E, Seibold-Schmid B, et al. Phenotypic associations of Crohn’s disease with antibodies to flagellins A4-Fla2 and Fla-X, ASCA, p-ANCA, PAB, and NOD2 mutations in a Swiss cohort. Inflamm Bowel Dis. 2009;15(9):1358–67.PubMedCentralPubMed
34.
Terjung B, Worman HJ, Herzog V, Sauerbruch T, Spengler U. Differentiation of antineutrophil nuclear antibodies in inflammatory bowel and autoimmune liver diseases from antineutrophil cytoplasmic antibodies (p-ANCA) using immunofluorescence microscopy. Clin Exp Immunol. 2001;126(1):37–46.PubMedCentralPubMed
35.
Franks I. IBD: CRP is a good long-term biomarker. Nat Rev Gastroenterol Hepatol. 2011;8(7):359.
36.
Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol. 2008;103(1):162–9.PubMed
37.
Schoepfer AM, Beglinger C, Straumann A, Trummler M, Vavricka SR, Bruegger LE, et al. Fecal calprotectin correlates more closely with the simple endoscopic score for Crohn’s disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol. 2010;105(1):162–9.PubMed
38.
Schoepfer AM, Trummler M, Seeholzer P, Seibold-Schmid B, Seibold F. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflamm Bowel Dis. 2008;14(1):32–9.PubMed
39.
Louis E, Belaiche J, van Kemseke C, Franchimont D, de Groote D, Gueenen V, et al. A high serum concentration of interleukin-6 is predictive of relapse in quiescent Crohn’s disease. Eur J Gastroenterol Hepatol. 1997;9(10):939–44.PubMed
40.
Bross DA, Leichtner AM, Zurakowski D, Law T, Bousvaros A. Elevation of serum interleukin-6 but not serum-soluble interleukin-2 receptor in children with Crohn’s disease. J Pediatr Gastroenterol Nutr. 1996;23(2):164–71.PubMed
41.••
Sipponen T, Kolho KL. Fecal calprotectin in diagnosis and clinical assessment of inflammatory bowel disease. Scand J Gastroenterol. 2015;50(1):74–80. Excellent review on the diagnostic value of calprotectin in inflammatory bowel disease.PubMed
42.••
Mooiweer E, Severs M, Schipper ME, Fidder HH, Siersema PD, Laheij RJ, et al. Low fecal calprotectin predicts sustained clinical remission in inflammatory bowel disease patients: a plea for deep remission. J Crohns Colitis. 2015;9(1):50–5. Intersting study showing the value of calprotectin in monitoring IBD patients: Low calprotectin levels in IBD patients predict a stable remission during follow-up.PubMed
43.
Louis E. Fecal calprotectin: towards a standardized use for inflammatory bowel disease management in routine practice. J Crohns Colitis. 2015;9(1):1–3.PubMed
44.••
Yamamoto T, Shiraki M, Bamba T, Umegae S, Matsumoto K. Fecal calprotectin and lactoferrin as predictors of relapse in patients with quiescent ulcerative colitis during maintenance therapy. Int J Color Dis. 2014;29(4):485–91. Another study showing the value of calprotectin for monitoring the course of inflammation in IBD patients: Calprotectin showed a higher sensitivity and specificity than lactoferrin for predicting a relapse in UC patients. Calprotectin level predicted a relapse in patients with quiescent UC.
45.
Yamamoto T. Letter: faecal calprotectin and lactoferrin—accurate biomarkers in post-operative Crohn’s disease? Aliment Pharmacol Ther. 2014;40(3):321.PubMed
46.••
Schoepfer AM, Beglinger C, Straumann A, Safroneeva E, Romero Y, Armstrong D, et al. Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes. Inflamm Bowel Dis. 2013;19(2):332–41. Important study showing that calprotectin levels are a surrogate marker for mucosal inflammation as they correlated better with endoscopic disease activity than clinical activity, CRP, platelets, hemoglobin, and blood leukocyte counts in CD patients.PubMed
47.
Rogler G, Aldeguer X, Kruis W, Lasson A, Mittmann U, Nally K, et al. Concept for a rapid point-of-care calprotectin diagnostic test for diagnosis and disease activity monitoring in patients with inflammatory bowel disease: expert clinical opinion. J Crohns Colitis. 2013;7(8):670–7.PubMed
48.
Schoepfer AM, Beglinger C, Straumann A, Trummler M, Renzulli P, Seibold F. Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes. Inflamm Bowel Dis. 2009;15(12):1851–8.PubMed
49.
Burri E, Beglinger C. IBD: faecal calprotectin testing—the need for better standardization. Nat Rev Gastroenterol Hepatol. 2014;11(10):583–4.PubMed
50.
Jones GR, Kennedy NA, Lees CW, Arnott ID, Satsangi J. Letter: faecal calprotectin and lactoferrin—accurate biomarkers in post-operative Crohn’s disease—authors’ reply. Letter: biologic therapies are effective for prevention of post-operative Crohn’s disease recurrence—authors’ reply. Aliment Pharmacol Ther. 2014;40(3):323.PubMed
51.
Yamamoto T, Shiraki M, Bamba T, Umegae S, Matsumoto K. Faecal calprotectin and lactoferrin as markers for monitoring disease activity and predicting clinical recurrence in patients with Crohn’s disease after ileocolonic resection: a prospective pilot study. U Eur Gastroenterol J. 2013;1(5):368–74.
52.
Dassopoulos T, Nguyen GC, Talor MV, Datta LW, Isaacs KL, Lewis JD, et al. NOD2 mutations and anti-Saccharomyces cerevisiae antibodies are risk factors for Crohn’s disease in African Americans. Am J Gastroenterol. 2010;105(2):378–86.PubMedCentralPubMed
53.
Marrakchi R, Bougatef K, Moussa A, Ouerhani S, Khodjet-el-Khil H, Messai Y, et al. 3020insC insertion in NOD2/CARD15 gene, a prevalent variant associated with anti-Saccharomyces cerevisiae antibodies and ileal location of Crohn’s disease in Tunisian population. Inflamm Res. 2009;58(4):218–23.PubMed
54.
Odes S, Friger M, Vardi H, Claessens G, Bossuyt X, Riis L, et al. Role of ASCA and the NOD2/CARD15 mutation Gly908Arg in predicting increased surgical costs in Crohn’s disease patients: a project of the European Collaborative Study Group on inflammatory bowel disease. Inflamm Bowel Dis. 2007;13(7):874–81.PubMed
55.
Abreu MT, Taylor KD, Lin YC, Hang T, Gaiennie J, Landers CJ, et al. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn’s disease. Gastroenterology. 2002;123(3):679–88.PubMed
56.
Carvalho AT, Esberard BC, Froes RS, Rapozo DC, Grinman AB, Simao TA, et al. Thiopurine-methyltransferase variants in inflammatory bowel disease: prevalence and toxicity in Brazilian patients. World J Gastroenterol. 2014;20(12):3327–34.PubMedCentralPubMed
57.
Dong XW, Zheng Q, Zhu MM, Tong JL, Ran ZH. Thiopurine S-methyltransferase polymorphisms and thiopurine toxicity in treatment of inflammatory bowel disease. World J Gastroenterol. 2010;16(25):3187–95.PubMedCentralPubMed
58.
Zelinkova Z, Derijks LJ, Stokkers PC, Vogels EW, van Kampen AH, Curvers WL, et al. Inosine triphosphate pyrophosphatase and thiopurine s-methyltransferase genotypes relationship to azathioprine-induced myelosuppression. Clin Gastroenterol Hepatol. 2006;4(1):44–9.PubMed
59.
Linssen J, Aderhold S, Nierhaus A, Frings D, Kaltschmidt C, Zanker K. Automation and validation of a rapid method to assess neutrophil and monocyte activation by routine fluorescence flow cytometry in vitro. Cytometry B Clin Cytom. 2008;74(5):295–309.PubMed
60.
Marafini I, Di Sabatino A, Zorzi F, Monteleone I, Sedda S, Cupi ML, et al. Serum regenerating islet-derived 3-alpha is a biomarker of mucosal enteropathies. Aliment Pharmacol Ther. 2014;40(8):974–81.PubMed
61.••
Zissimopoulos A, Vradelis S, Konialis M, Chadolias D, Bampali A, Constantinidis T, et al. Chromogranin A as a biomarker of disease activity and biologic therapy in inflammatory bowel disease: a prospective observational study. Scand J Gastroenterol. 2014;49(8):942–9. Serum levels of Chromogranin A were found to be a reliable marker of disease activity in IBD patients and especially in those who received biologic therapy. No comparison to calprotectin was performed.PubMed
62.
Kovacs M, Muller KE, Papp M, Lakatos PL, Csondes M, Veres G. New serological markers in pediatric patients with inflammatory bowel disease. World J Gastroenterol. 2014;20(17):4873–82.PubMedCentralPubMed
63.••
Voiosu T, Balanescu P, Bengus A, Voiosu A, Baicus CR, Barbu M, et al. Serum endocan levels are increased in patients with inflammatory bowel disease. Clin Lab. 2014;60(3):505–10. Endocan is a marker of angiogenesis. In a group of 33 consecutive IBD patients from an observational cohort study endocan levels were significantly higher in the IBD group as compared to healthy controls, however, there was no correlation between endocan levels and disease activity.PubMed
64.••
Schaffer T, Schoepfer AM, Seibold F, Swiss IBDCSG. Serum ficolin-2 correlates worse than fecal calprotectin and CRP with endoscopic Crohn’s disease activity. J Crohns Colitis. 2014;8(9):1125–32. Ficolin, another serum protein, is not superior as compared to calprotectin in the monitoring of IBD patients.PubMed
65.
Kofla-Dlubacz A, Matusiewicz M, Krzesiek E, Noga L, Iwanczak B. Metalloproteinase-3 and -9 as novel markers in the evaluation of ulcerative colitis activity in children. Adv Clin Exp Med : Off Organ Wroclaw Med Univ. 2014;23(1):103–10.
66.
Morisaki T, Takeshima F, Fukuda H, Matsushima K, Akazawa Y, Yamaguchi N, et al. High serum vaspin concentrations in patients with ulcerative colitis. Dig Dis Sci. 2014;59(2):315–21.PubMed
67.
Tsui FW, Tsui HW, Las Heras F, Pritzker KP, Inman RD. Serum levels of novel noggin and sclerostin-immune complexes are elevated in ankylosing spondylitis. Ann Rheum Dis. 2014;73(10):1873–9.PubMed
68.
Schoepfer AM, Dehlavi MA, Fournier N, Safroneeva E, Straumann A, Pittet V, et al. Diagnostic delay in Crohn’s disease is associated with a complicated disease course and increased operation rate. Am J Gastroenterol. 2013;108(11):1744–53. quiz 1754.PubMed
69.
Vavricka SR, Spigaglia SM, Rogler G, Pittet V, Michetti P, Felley C, et al. Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18(3):496–505.PubMed
70.
Ashorn S, Honkanen T, Kolho KL, Ashorn M, Valineva T, Wei B, et al. Fecal calprotectin levels and serological responses to microbial antigens among children and adolescents with inflammatory bowel disease. Inflamm Bowel Dis. 2009;15(2):199–205.PubMedCentralPubMed
71.
Canani RB, Terrin G, Rapacciuolo L, Miele E, Siani MC, Puzone C, et al. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. Dig Liver Dis. 2008;40(7):547–53.PubMed
72.
Carroccio A, Iacono G, Cottone M, Di Prima L, Cartabellotta F, Cavataio F, et al. Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and children. Clin Chem. 2003;49(6 Pt 1):861–7.PubMed
73.
Caviglia GP, Pantaleoni S, Touscoz GA, Adriani A, Rosso C, Smedile A, et al. Fecal calprotectin is an effective diagnostic tool that differentiates inflammatory from functional intestinal disorders. Scand J Gastroenterol. 2014;49(12):1419–24.PubMed
74.••
D’Haens G, Ferrante M, Vermeire S, Baert F, Noman M, Moortgat L, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18(12):2218–24. The title nicely relfects the important meassage: Fecal calprotectin can be clinically used as a surrogate marker for endoscopic lesions in IBD avoiding some endoscopies during monitoring of patients.PubMed
75.
Kennedy NA, Clark A, Walkden A, Chang JC, Fasci-Spurio F, Muscat M, et al. Clinical utility and diagnostic accuracy of faecal calprotectin for IBD at first presentation to gastroenterology services in adults aged 16–50 years. J Crohns Colitis. 2015;9(1):41–9.PubMed
76.
Konikoff MR, Denson LA. Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. Inflamm Bowel Dis. 2006;12(6):524–34.PubMed
77.
van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ. 2010;341:c3369.PubMedCentralPubMed
78.
Easton JA, Hardwicke J, Whitehead PH. The estimation of two alpha(1) glycoproteins (orosomucoid and another alpha(1) acid glycoprotein) in health and disease. J Clin Pathol. 1962;15(6):585–90.PubMedCentralPubMed
79.
Kjeldsen J, Lauritsen K, De Muckadell OB. Serum concentrations of orosomucoid: improved decision-making for tapering prednisolone therapy in patients with active inflammatory bowel disease? Scand J Gastroenterol. 1997;32(9):933–41.PubMed
80.
Shah A, Morgan G, Rose JD, Fifield R, Rhodes J. Platelet number and size in relation to serum orosomucoid concentration in Crohn’s disease. Med Lab Sci. 1989;46(1):79–80.PubMed
81.
Kruis W, Fateh-Mogadam A, Sandel P. Serum levels of beta 2-microglobulin: a new marker of activity in Crohn’s disease. N Engl J Med. 1979;301(24):1348.PubMed
82.
Manicourt DH, Orloff S. Serum levels of beta 2-microglobulin in Crohn’s disease. N Engl J Med. 1980;302(12):696.PubMed
83.
Ricci G, D’Ambrosi A, Resca D, Masotti M, Alvisi V. Comparison of serum total sialic acid, C-reactive protein, alpha 1-acid glycoprotein and beta 2-microglobulin in patients with non-malignant bowel diseases. Biomed Pharmacother. 1995;49(5):259–62.PubMed
84.
Yilmaz B, Koklu S, Yuksel O, Arslan S. Serum beta 2-microglobulin as a biomarker in inflammatory bowel disease. World J Gastroenterol. 2014;20(31):10916–20.PubMedCentralPubMed
85.
Chambers RE, Stross P, Barry RE, Whicher JT. Serum amyloid A protein compared with C-reactive protein, alpha 1-antichymotrypsin and alpha 1-acid glycoprotein as a monitor of inflammatory bowel disease. Eur J Clin Invest. 1987;17(5):460–7.PubMed
86.
De Beer FC, Mallya RK, Fagan EA, Lanham JG, Hughes GR, Pepys MB. Serum amyloid-A protein concentration in inflammatory diseases and its relationship to the incidence of reactive systemic amyloidosis. Lancet. 1982;2(8292):231–4.PubMed
87.
Lopes S, Figueiredo P, Portela F, Freire P, Almeida N, Lerias C, et al. Capsule endoscopy in inflammatory bowel disease type unclassified and indeterminate colitis serologically negative. Inflamm Bowel Dis. 2010;16(10):1663–8.PubMed
88.
Geboes K, Van Eyken P. Inflammatory bowel disease unclassified and indeterminate colitis: the role of the pathologist. J Clin Pathol. 2009;62(3):201–5.PubMed
89.
Vermeire S, Joossens S, Peeters M, Monsuur F, Marien G, Bossuyt X, et al. Comparative study of ASCA (ANTI-SACCHAROMYCES cerevisiae antibody) assays in inflammatory bowel disease. Gastroenterology. 2001;120(4):827–33.PubMed
90.
Reese GE, Constantinides VA, Simillis C, Darzi AW, Orchard TR, Fazio VW, et al. Diagnostic precision of anti-Saccharomyces cerevisiae antibodies and perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Am J Gastroenterol. 2006;101(10):2410–22.PubMed
91.
Peeters M, Joossens S, Vermeire S, Vlietinck R, Bossuyt X, Rutgeerts P. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol. 2001;96(3):730–4.PubMed
92.
Joossens S, Reinisch W, Vermeire S, Sendid B, Poulain D, Peeters M, et al. The value of serologic markers in indeterminate colitis: a prospective follow-up study. Gastroenterology. 2002;122(5):1242–7.PubMed
93.
Dotan I. Serologic markers in inflammatory bowel disease: tools for better diagnosis and disease stratification. Exp Rev Gastroenterol Hepatol. 2007;1(2):265–74.
94.
Dotan I, Fishman S, Dgani Y, Schwartz M, Karban A, Lerner A, et al. Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn’s disease. Gastroenterology. 2006;131(2):366–78.PubMed
95.
Amre DK, Lu SE, Costea F, Seidman EG. Utility of serological markers in predicting the early occurrence of complications and surgery in pediatric Crohn’s disease patients. Am J Gastroenterol. 2006;101(3):645–52.PubMed
96.
Desir B, Amre DK, Lu SE, Ohman-Strickland P, Dubinsky M, Fisher R, et al. Utility of serum antibodies in determining clinical course in pediatric Crohn’s disease. Clin Gastroenterol Hepatol. 2004;2(2):139–46.PubMed
97.
Ippoliti A, Devlin S, Mei L, Yang H, Papadakis KA, Vasiliauskas EA, et al. Combination of innate and adaptive immune alterations increased the likelihood of fibrostenosis in Crohn’s disease. Inflamm Bowel Dis. 2010;16(8):1279–85.PubMed
98.
Dubinsky MC, Lin YC, Dutridge D, Picornell Y, Landers CJ, Farrior S, et al. Serum immune responses predict rapid disease progression among children with Crohn’s disease: immune responses predict disease progression. Am J Gastroenterol. 2006;101(2):360–7.PubMedCentralPubMed
99.
Arnott ID, Landers CJ, Nimmo EJ, Drummond HE, Smith BK, Targan SR, et al. Sero-reactivity to microbial components in Crohn’s disease is associated with disease severity and progression, but not NOD2/CARD15 genotype. Am J Gastroenterol. 2004;99(12):2376–84.PubMed
100.
Annese V, Lombardi G, Perri F, D’Inca R, Ardizzone S, Riegler G, et al. Variants of CARD15 are associated with an aggressive clinical course of Crohn’s disease—an IG-IBD study. Am J Gastroenterol. 2005;100(1):84–92.PubMed
101.
Devlin SM, Yang H, Ippoliti A, Taylor KD, Landers CJ, Su X, et al. NOD2 variants and antibody response to microbial antigens in Crohn’s disease patients and their unaffected relatives. Gastroenterology. 2007;132(2):576–86.PubMed
102.
Fagan EA, Dyck RF, Maton PN, Hodgson HJ, Chadwick VS, Petrie A, et al. Serum levels of C-reactive protein in Crohn’s disease and ulcerative colitis. Eur J Clin Invest. 1982;12(4):351–9.PubMed
103.
Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut. 2006;55(3):426–31.PubMedCentralPubMed
104.••
Molander P, Farkkila M, Ristimaki A, Salminen K, Kemppainen H, Blomster T, et al. Does fecal calprotectin predict short-term relapse after stopping tnfalpha-blocking agents in inflammatory bowel disease patients in deep remission? J Crohns Colitis. 2015;9(1):33–40. Fecal calprotectin was found to increase and remain elevated before clinical or endoscopic relapse in patients that stop anti-TNF therapy. The authors subsequently suggest “that it can be used as a surrogate marker for predicting and identifying patients requiring close follow-up in clinical practice”.PubMed
105.
Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology. 2000;119(1):15–22.PubMed
106.••
Osterman MT, Aberra FN, Cross R, Liakos S, McCabe R, Shafran I, et al. Mesalamine dose escalation reduces fecal calprotectin in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol. 2014;12(11):1887–1893 e1883. The first study showing that a clinical intervention (increase of 5-ASA) based on calprotectin levels during monitoring can be beneficial for the long-term outcome.PubMed
107.••
Lasson A, Strid H, Ohman L, Isaksson S, Olsson M, Rydstrom B, et al. Fecal calprotectin one year after ileocaecal resection for Crohn’s disease—a comparison with findings at ileocolonoscopy. J Crohns Colitis. 2014;8(8):789–95. Calprotectin predicts postoperative relaps and may be used in the postoperative setting to monitor IBD patients.PubMed
108.
Yamamoto T, Kotze PG. Is fecal calprotectin useful for monitoring endoscopic disease activity in patients with postoperative Crohn’s disease? J Crohns Colitis. 2013;7(12):e712.PubMed
109.••
Lobaton T, Lopez-Garcia A, Rodriguez-Moranta F, Ruiz A, Rodriguez L, Guardiola J. A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn’s disease. J Crohns Colitis. 2013;7(12):e641–51. Rapids tests may have the same potential as compared to standard ELISAs.PubMed
110.
Seibold F, Schoepfer AM. Can fecal calprotectin or lactoferrin identify postoperative recurrence in Crohn’s disease? Inflamm Bowel Dis. 2010;16(10):1814–5.PubMed
111.
Lamb CA, Mohiuddin MK, Gicquel J, Neely D, Bergin FG, Hanson JM, et al. Faecal calprotectin or lactoferrin can identify postoperative recurrence in Crohn’s disease. Br J Surg. 2009;96(6):663–74.PubMed
112.
Wright E, De Cruz P, Hamilton A, Ritchie K, Krejany S, Leach S, et al. Faecal calprotectin helps determine the need for post-operative colonoscopy in Crohn’s disease. Prospective longitudinal endoscopic validation. Results from the POCER study. UEG J. 2013;1 Suppl 1:A35.
Metadata
Title
Clinical Utility of Biomarkers in IBD
Authors
Gerhard Rogler
Luc Biedermann
Publication date
01-07-2015
Publisher
Springer US
Published in
Current Gastroenterology Reports / Issue 7/2015
Print ISSN: 1522-8037
Electronic ISSN: 1534-312X
DOI
https://doi.org/10.1007/s11894-015-0449-x
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits